INVESTORS
About
The company has a product for blood biomarker testing. The product is ready for the market in 2019. Customers demand this type of product and several contacts have already been made with vital institutions in Denmark.
Investors
Qlife Holding AB aims to simplify the market evaluation of the company through clear information. If you’re interested in the coming IPO offering, there is a possibility to make a registration. The preliminary start of the subscription period is January, 2020.
Egoo.health
The Egoo product is a platform for accurate bio-marker testing. At a low cost and with equipment easy to use, it measures and analyses the patient’s blood. The patient can do the testing at home themselves. Read more on our product page.
IPO OFFERING
If you’re interested in the coming IPO offering, please sign up your name and e-mail address below. You will receive an offering to subscribe when the subscription period is initiated, preliminarily in January, 2020.
In less than four minutes, CEO Thomas Warthoe explains what Egoo Health is all about, how it works and why it makes a difference for ordinary people, medical staff and health institutions.